Preliminary fabrication of tissue engineered veins containing valves using bone marrow mesenchymal stem cells and biodegradable scaffolds in vitro

doi:10.3969/j.issn.2095-4344.2014.03.004

Abstract

Abstract:

BACKGROUND: Chronic venous insufficiency is a major health problem worldwide. Clinical treatments include venous valve repair and venous segment containing valve transplantation. However, these are invasive procedures, and the supply of vein containing valves is limited. Significant progress in the fields of tissue engineering and regenerative medicine has been made towards the creation of tissue engineered vascular grafts for the repair of damaged or malformed vessels. It has been reported that using tissue engineering, a tissue engineered vein containing valves constructed with self-derived endothelial cells and allogeneic acellular matrices can provide the complex physiological valve structure and mechanical stability, but this elicited an immunogenic response.
OBJECTIVE: To create a viable and functional vein containing valves, which has the ability to grow, repair, and imitate natural tissues.
METHODS: Bone marrow mesenchymal stem cells were obtained from Beagle dogs by density gradient centrifugation and adherence methods. Bone marrow mesenchymal stem cells were cultured in vitro. Following isolation and culture the cells were examined using flow cytometry and identified by direct induction towards the osteogenic and adipogenic lineages. We fabricated biodegradable venous scaffold containing valves using the method of injection molding combined with thermally induced phase separation. Based on the self-made cast, a three-dimensional biodegradable vein scaffold containing valves was constructed from poly(lactic-co-glycolic acid). Morphological structure was tested. Bone marrow mesenchymal stem cells were used as seed cells to be seeded onto the lumen of the tissue engineered vein scaffold containing valves in vitro and then incubated for 2 weeks.
RESULTS AND CONCLUSION: Scanning electron microscopy images showed that the scaffold demonstrated sufficient porosity. Cultured cells expressed mesenchymal cell markers, CD44 and CD29, but did not express hematopoietic cell markers, CD34 and CD45 at the same time point. Scaffolds were nontoxic to cells and were favorable for the growth and migration of bone marrow mesenchymal stem cells. Cells attached on the surface of poly(lactic-co-glycolic acid) scaffolds formed a confluent layer after incubation. The cellular constructs were tested in vitro, and the valve leaflets were functionally capable of opening and closing when stimulated. These results suggested that the tissue engineered vein containing valves have been successfully constructed by using a three-dimensional poly(lactic-co-glycolic acid) scaffold and bone marrow mesenchymal stem cells as seed cells. Tissue engineered vein containing valves is potentially useful for the substitution and regeneration of vein valves.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: biocompatible materials, venous insufficiency, mesenchymal stem cells, venous valves

CLC Number:

R318

Liu Chi-zhuai, Yin Heng-hui, Lv Wei-ming, Zeng Chen-guang, Liu Chang, Wang Wen-jian, Quan Da-ping, Xiang Peng, Wang Shen-ming. Preliminary fabrication of tissue engineered veins containing valves using bone marrow mesenchymal stem cells and biodegradable scaffolds in vitro[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(3): 348-356.

Figures/Tables 5

References

[1]Gohel MS, Barwell JR, Taylor M, et al. Long Term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ. 2007;335(7610):83.

[2]Taheri SA, Schultz RO. Experimental prosthetic vein valve. long-term results. Angiology. 1995;46(4):299-303.

[3]Hill R, Schmidt S, Evancho M, et al. Development of a prosthetic venous valve. J Biomed Mater Res.1985; 19(7): 827-832.

[4]Pavcnik D, Uchida BT, Timmermans HA, et al. Percutaneous bioprosthetic venous valve: a long-term study in sheep. J Vasc Surg. 2002;35(3):598-602.

[5]Teebken OE, Puschmann C, Aper T, et al. Tissue-engineered bioprosthetic venous valve: a long-term study in sheep. Eur J Vasc Endovasc Surg. 2003;25(4): 305-312.

[6]Cho SW, Park HJ, Ryu JH, et al. Vascular patches tissue-engineered with autologous bone marrow-derived cells and decellularized tissue matrices. Biomaterials. 2005; 26(14):1915-1924.

[7]Zhao Y, Zhang S, Zhou J, et al. The development of a tissue-engineered artery using decellularized scaffold and autologous ovine mesenchymal stem cells. Biomaterials. 2010;31(2):296-307.

[8]The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.

[9]Gong Z, Niklason LE. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (Hmscs). FASEB J. 2008;22(6):1635-1648.

[10]Cho SW, Lim SH, Kim IK, et al. Small-diameter blood vessels engineered with bone marrow-derived cells. Ann Surg. 2005;241(3):506-515.

[11]Teebken OE, Puschmann C, Breitenbach I, et al. Preclinical development of tissue-engineered vein valves and venous substitutes using re-endothelialised human vein matrix. Eur J Vasc Endovasc Surg. 2009;37(1):92-102.

[12]Kabbani L, Escobar GA, Mansour F, et al. Longevity and outcomes of axillary valve transplantation for severe lower extremity chronic venous insufficiency. Ann Vasc Surg. 2011;25(4):496-501.

[13]Akesson H, Risberg B, Björgell O. External support valvuloplasty in the treatment of chronic deep vein incompetence of the legs. Int Angiol. 1999;18(3): 233-238.

[14]Maleti O, Perrin M. Reconstructive surgery for deep vein reflux in the lower limbs: techniques, results and indications. Eur J Vasc Endovasc Surg. 2011;41(6):837-848.

[15]Pavcnik D, Uchida B, Kaufman J, et al. Percutaneous management of chronic deep venous reflux: review of experimental work and early clinical experience with bioprosthetic valve. Vasc Med. 2008;13(1):75-84.

[16]Gale SS, Shuman S, Beebe HG, et al. Percutaneous venous valve bioprosthesis: initial observations. Vasc Endovascular Surg. 2004;38(3):221-224.

[17]Wang Z, Zhang Z, Zhang JC, et al. Distribution of bone marrow stem cells in large porous polyester scaffolds. Chin Sci Bull. 2009;54(17):2968-2975.

[18]Soletti L, Hong Y, Guan J, et al. A bilayered elastomeric scaffold for tissue engineering of small diameter vascular grafts. Acta Biomater. 2010;6(1):110-122.

[19]Zhang WJ, Liu W, Cui L, et al. Tissue engineering of blood vessel. J Cell Mol Med. 2007;11(5):945-957.

[20]Shao HJ, Chen CS, Lee IC, et al. Designing a three-dimensional expanded polytetrafluoroethylene- poly(lactic-co-glycolic acid) scaffold for tissue engineering. Artif Organs. 2009;33(4): 309-317.

[21]Cancedda R, Giannoni P, Mastrogiacomo M. A Tissue engineering approach to bone repair in large animal models and in clinical practice. Biomaterials. 2007;28(29): 4240-4250.

[22]Ma Z, Gao C, Gong Y, et al. Paraffin spheres as porogen to fabricate poly(l-lactic acid) scaffolds with improved cytocompatibility for cartilage tissue engineering. J Biomed Mater Res B Appl Biomater. 2003;67(1):610-617.

[23]Hu X, Shen H, Yang F, et al. Preparation and cell affinity of microtubular orientation-structured plga(70/30) blood vessel scaffold. Biomaterials. 2008;29(21):3128-3136.

[24]Wu L, Zhang J, Jing D, et al. "Wet-State" mechanical properties of three-dimensional polyester porous scaffolds. J Biomed Mater Res A. 2006;76(2):264-271.

[25]Xie S, Zhu Q, Wang B, et al. Incorporation of tripolyphosphate nanoparticles into fibrous poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2010;31(19):5100-5109.

[26]Leung L, Chan C, Baek S, et al. Comparison of morphology and mechanical properties of PLGA bioscaffolds. Biomed Mater. 2008;3(2):025006.

[27]Oh SH, Kang SG, Kim ES, et al. Fabrication and characterization of hydrophilic poly(lactic-co-glycolic acid)/poly(vinyl alcohol) blend cell scaffolds by melt-molding particulate-leaching method. Biomaterials. 2003;24(22):4011-4021.

[28]O'Cearbhaill ED, Murphy M, Barry F, Et al. Behavior of human mesenchymal stem cells in fibrin-based vascular tissue engineering constructs. Ann Biomed Eng. 2010; 38(3):649-657.

[29]Zhang L, Zhou J, Lu Q, et al. A Novel small-diameter vascular graft: in vivo behavior of biodegradable three-layered tubular scaffolds. Biotechnol Bioeng. 2008;99(4):1007-1015.

[30]Hashi CK, Zhu Y, Yang GY, et al. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci U S A. 2007;104(29): 11915-11920.

[31]Matsumura G, Miyagawa-Tomita S, Shin'oka T, et al. First Evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation. 2003;108(14):1729-1734.

[32]O'Cearbhaill ED, Punchard MA, Murphy M, et al. Response of mesenchymal stem cells to the biomechanical environment of the endothelium on a flexible tubular silicone substrate. Biomaterials. 2008;29(11):1610-1619. 42(3):467-475.